BNP Paribas Financial Markets Has $501,000 Stock Holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

BNP Paribas Financial Markets lifted its position in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) by 1,335.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 43,296 shares of the specialty pharmaceutical company’s stock after purchasing an additional 40,280 shares during the quarter. BNP Paribas Financial Markets owned 0.10% of KalVista Pharmaceuticals worth $501,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in KALV. FMR LLC raised its stake in KalVista Pharmaceuticals by 22.9% during the 3rd quarter. FMR LLC now owns 66,423 shares of the specialty pharmaceutical company’s stock worth $769,000 after buying an additional 12,397 shares during the period. Citigroup Inc. raised its position in shares of KalVista Pharmaceuticals by 6.8% during the third quarter. Citigroup Inc. now owns 305,504 shares of the specialty pharmaceutical company’s stock worth $3,538,000 after purchasing an additional 19,440 shares during the period. Intech Investment Management LLC acquired a new stake in shares of KalVista Pharmaceuticals during the third quarter worth about $126,000. Connor Clark & Lunn Investment Management Ltd. lifted its holdings in shares of KalVista Pharmaceuticals by 114.4% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 22,949 shares of the specialty pharmaceutical company’s stock valued at $266,000 after purchasing an additional 12,245 shares in the last quarter. Finally, Quest Partners LLC acquired a new position in shares of KalVista Pharmaceuticals in the 3rd quarter valued at approximately $175,000.

Insider Transactions at KalVista Pharmaceuticals

In related news, CEO Benjamin L. Palleiko sold 7,627 shares of the company’s stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $9.75, for a total transaction of $74,363.25. Following the sale, the chief executive officer now owns 274,596 shares in the company, valued at approximately $2,677,311. This represents a 2.70 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Paul K. Audhya sold 8,077 shares of the firm’s stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $9.26, for a total value of $74,793.02. Following the completion of the transaction, the insider now owns 94,199 shares of the company’s stock, valued at approximately $872,282.74. This represents a 7.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 32,291 shares of company stock valued at $304,086 in the last ninety days. 10.50% of the stock is currently owned by corporate insiders.

KalVista Pharmaceuticals Stock Performance

Shares of KalVista Pharmaceuticals stock opened at $8.69 on Friday. The firm has a market cap of $429.46 million, a PE ratio of -2.39 and a beta of 0.85. The business’s 50 day simple moving average is $10.65 and its 200 day simple moving average is $11.74. KalVista Pharmaceuticals, Inc. has a 52-week low of $8.48 and a 52-week high of $16.88.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on KALV. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of KalVista Pharmaceuticals in a research note on Monday, December 9th. HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of KalVista Pharmaceuticals in a report on Friday, December 6th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $28.00 price objective on shares of KalVista Pharmaceuticals in a research report on Thursday, December 5th.

KalVista Pharmaceuticals Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).